Effects of two types of exercise training on psychological well-being, sleep, quality of life and physical fitness in patients with high-grade glioma (WHO III and IV): study protocol for a randomized controlled trial.
Anxiety
Brain
Control condition
Exercise
Glioma
Perceived stress
Quality of life
Sleep
Training
Tumor
Journal
Cancer communications (London, England)
ISSN: 2523-3548
Titre abrégé: Cancer Commun (Lond)
Pays: United States
ID NLM: 101723675
Informations de publication
Date de publication:
09 08 2019
09 08 2019
Historique:
received:
03
05
2019
accepted:
02
08
2019
entrez:
11
8
2019
pubmed:
11
8
2019
medline:
27
5
2020
Statut:
epublish
Résumé
There is existing evidence on whether and to what degree regular exercise training improves the quality of life (QoL) among cancer survivors. However, in regards to patients with high-grade glioma (HGG; WHO grade III and IV), no conclusive study has been performed so far. The present trial aims to fill this gap by examining whether psychological well-being, sleep, QoL and physical fitness might be improved with two different types of exercise, as compared to an active control condition. Active control condition represent individuals participating at regular meetings to talk about their current life situation, though, the meetings were not intended as that of the psychotherapy group. Regular meetings are of the same frequency, duration, and intensity as the exercise interventions. A total of 45 patients with HGG after undergoing neurosurgery and adjuvant radiotherapy, chemotherapy, or chemoradiotherapy will be consecutively and randomly assigned to (a) an endurance training, (b) a resistance training or (c) to an active control condition. The intervention will last for 6 consecutive weeks, consisting of 2 weekly sessions (30-45 min per session). Measurements would take place at three time points, namely at the beginning of the study (baseline), 3 weeks after the beginning of the study, and 6 weeks after the beginning of the study. The last measurement also represents the end of the study. Aerobic exercise performance will be assessed objectively with a 6-min walking test, and a handgrip test will be used to assess the upper body strength. Further, participants will complete a battery of questionnaires covering sociodemographic information, QoL, sleep quality and sleep patterns, coping with stress, state- and trait-anxiety, depression, and fatigue. In parallel, experts will use the Hamilton Depression Rating Scale to determine and rate participants' symptoms of depression. The present study will be the first to investigate and compare the impact of two different exercise modalities, namely endurance and resistance training, on physical fitness and dimensions of well-being, and sleep among patients with HGG who underwent neurosurgery followed by adjuvant radiotherapy, chemotherapy, or chemoradiotherapy. Importantly, unlike the majority of previous studies, the control condition consists of an active set-up to detect possible factual beneficial effects of exercise training, irrespective of social interactions. Trial registration https://register.clinicaltrials.gov ; identifier: NCT03775369.
Sections du résumé
BACKGROUND
There is existing evidence on whether and to what degree regular exercise training improves the quality of life (QoL) among cancer survivors. However, in regards to patients with high-grade glioma (HGG; WHO grade III and IV), no conclusive study has been performed so far. The present trial aims to fill this gap by examining whether psychological well-being, sleep, QoL and physical fitness might be improved with two different types of exercise, as compared to an active control condition. Active control condition represent individuals participating at regular meetings to talk about their current life situation, though, the meetings were not intended as that of the psychotherapy group. Regular meetings are of the same frequency, duration, and intensity as the exercise interventions.
METHODS
A total of 45 patients with HGG after undergoing neurosurgery and adjuvant radiotherapy, chemotherapy, or chemoradiotherapy will be consecutively and randomly assigned to (a) an endurance training, (b) a resistance training or (c) to an active control condition. The intervention will last for 6 consecutive weeks, consisting of 2 weekly sessions (30-45 min per session). Measurements would take place at three time points, namely at the beginning of the study (baseline), 3 weeks after the beginning of the study, and 6 weeks after the beginning of the study. The last measurement also represents the end of the study. Aerobic exercise performance will be assessed objectively with a 6-min walking test, and a handgrip test will be used to assess the upper body strength. Further, participants will complete a battery of questionnaires covering sociodemographic information, QoL, sleep quality and sleep patterns, coping with stress, state- and trait-anxiety, depression, and fatigue. In parallel, experts will use the Hamilton Depression Rating Scale to determine and rate participants' symptoms of depression.
SIGNIFICANCE
The present study will be the first to investigate and compare the impact of two different exercise modalities, namely endurance and resistance training, on physical fitness and dimensions of well-being, and sleep among patients with HGG who underwent neurosurgery followed by adjuvant radiotherapy, chemotherapy, or chemoradiotherapy. Importantly, unlike the majority of previous studies, the control condition consists of an active set-up to detect possible factual beneficial effects of exercise training, irrespective of social interactions. Trial registration https://register.clinicaltrials.gov ; identifier: NCT03775369.
Identifiants
pubmed: 31399142
doi: 10.1186/s40880-019-0390-8
pii: 10.1186/s40880-019-0390-8
pmc: PMC6688275
doi:
Banques de données
ClinicalTrials.gov
['NCT03775369']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Références
J Adolesc Health. 2014 Jan;54(1):109-13
pubmed: 23998848
Prog Brain Res. 2010;185:105-29
pubmed: 21075236
J Psychiatr Res. 2018 Dec;107:48-56
pubmed: 30317101
J Psychiatr Res. 2009 Oct;43(15):1231-4
pubmed: 19435635
Med Sci Sports Exerc. 2003 Nov;35(11):1846-52
pubmed: 14600549
JAMA Netw Open. 2019 Apr 5;2(4):e192810
pubmed: 31026026
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
Acta Neuropsychiatr. 2017 Apr;29(2):65-71
pubmed: 27145824
Z Rheumatol. 2005 May;64(4):255-64
pubmed: 15909086
Sports Med. 2018 Jul;48(7):1541-1559
pubmed: 29675670
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
pubmed: 25304271
J Adolesc Health. 2012 Dec;51(6):615-22
pubmed: 23174473
Neuropsychobiology. 2017;75(1):12-20
pubmed: 28750407
Sleep Med Rev. 2016 Aug;28:32-45
pubmed: 26447947
JACC Heart Fail. 2018 Jul;6(7):596-604
pubmed: 29957192
Neuropsychobiology. 2016;73(3):148-59
pubmed: 27064792
Int J Sports Med. 2013 Jul;34(7):631-6
pubmed: 23444095
BMC Gastroenterol. 2017 Dec 12;17(1):160
pubmed: 29233119
Front Psychol. 2018 Mar 13;9:249
pubmed: 29593592
Neuropsychobiology. 2017;76(2):59-71
pubmed: 29694980
PeerJ. 2016 Dec 15;4:e2790
pubmed: 27994983
J Health Psychol. 2009 Nov;14(8):1144-55
pubmed: 19858334
Chest. 2001 Jan;119(1):256-70
pubmed: 11157613
J Psychiatr Res. 2013 Jul;47(7):908-15
pubmed: 23583029
JAMA Intern Med. 2014 Mar;174(3):357-68
pubmed: 24395196
Neuropsychiatr Dis Treat. 2015 Aug 05;11:1911-20
pubmed: 26346856
Front Psychiatry. 2018 Jul 19;9:305
pubmed: 30072923
Sleep Med Rev. 2006 Oct;10(5):323-37
pubmed: 16564189
J Adolesc Health. 2010 Feb;46(2):133-41
pubmed: 20113919
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Breast Cancer Res Treat. 2013 Jan;137(1):175-86
pubmed: 23139058
J Affect Disord. 2016 Jan 15;190:249-253
pubmed: 26523669
Prog Neurol Surg. 2018;30:1-11
pubmed: 29241168
Behav Sleep Med. 2014;12(6):444-54
pubmed: 24229399
Curr Oncol. 2017 Aug;24(4):e290-e315
pubmed: 28874900
Clin Pract Epidemiol Ment Health. 2007 Jul 09;3:8
pubmed: 17620123
Eur Psychiatry. 2018 Oct;54:124-144
pubmed: 30257806
Sleep Med Rev. 2018 Aug;40:183-195
pubmed: 29395984
Behav Sleep Med. 2016 Nov-Dec;14(6):602-14
pubmed: 26507446
Sleep Med. 2008 Jul;9(5):517-26
pubmed: 17765011
Disabil Rehabil. 2015;37(16):1490-5
pubmed: 25342564
Neuropsychiatr Dis Treat. 2015 Feb 03;11:263-71
pubmed: 25678791
Neuropsychobiology. 2009;59(4):191-8
pubmed: 19521110
Psychother Psychosom. 2005;74(6):353-61
pubmed: 16244511
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Physiotherapy. 2012 Dec;98(4):277-86
pubmed: 23122432
Curr Oncol. 2017 Feb;24(1):40-46
pubmed: 28270724
BMC Psychiatry. 2016 May 31;16:174
pubmed: 27245844
Psychiatry Res. 2018 Feb;260:318-323
pubmed: 29227895
Med Care. 1988 Jul;26(7):724-35
pubmed: 3393032
J Behav Med. 2015 Jun;38(3):427-49
pubmed: 25596964
Neuropsychiatr Dis Treat. 2016 Aug 05;12:1977-81
pubmed: 27540294
Cogn Behav Ther. 2018 Sep;47(5):431-446
pubmed: 29893182
Neuropsychobiology. 2019;78(2):95-103
pubmed: 30970367
Psychiatr Danub. 2015 Sep;27(3):210-24
pubmed: 26400128
Neuropsychiatr Dis Treat. 2016 Oct 12;12:2617-2625
pubmed: 27789950
World J Biol Psychiatry. 2015 Feb;16(2):96-105
pubmed: 24564532
World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):465-75
pubmed: 19606405
Best Pract Res Clin Rheumatol. 2015 Feb;29(1):120-30
pubmed: 26267006
Neuropsychiatr Dis Treat. 2016 Jun 27;12:1571-9
pubmed: 27390520
BMC Pulm Med. 2015 Aug 12;15:89
pubmed: 26264470
Sleep Med Rev. 2015 Apr;20:59-72
pubmed: 25127157